Mitral Transcatheter Edge-to-Edge Repair and Clinical Value of Novel Echocardiographic Biomarkers: A Hypothesis-Generating Study.

cardiovascular death heart failure hospitalization left atrial strain mitral regurgitation myocardial work transcatheter edge-to-edge repair ventricle–pulmonary artery coupling

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
01 Aug 2024
Historique:
received: 12 06 2024
revised: 25 07 2024
accepted: 30 07 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: epublish

Résumé

Longitudinal data on reverse cardiac remodeling and outcomes after transcatheter edge-to-edge repair (TEER) are limited. A total of 78 patients with severe mitral regurgitation (MR) were included retrospectively. All patients had echocardiography at baseline and again six months after TEER. They were monitored for a primary composite endpoint, consisting of heart failure hospitalization and cardiovascular death, over 13 months. Significant decreases in the left ventricular ejection fraction (LVEF), all myocardial work indices (except global wasted work), and the left atrial reservoir were observed after TEER. Additionally, there was a decrease in the pulmonary artery systolic pressure and an increase in the tricuspid annular plane systolic excursion/pulmonary artery systolic pressure (TAPSE/PASP) ratio. A post-TEER TAPSE/PASP ratio of <0.47 (HR: 4.76, Echocardiography post-TEER reflects impairment in ventricular performance due to preload reduction and right ventricle and pulmonary artery coupling improvement. Short-term echocardiography after TEER identifies high-risk patients who could benefit from a close clinical follow-up. The prognostic significance of LA strain and the TAPSE/PASP ratio should be validated in subsequent large-scale prospective studies.

Sections du résumé

BACKGROUND BACKGROUND
Longitudinal data on reverse cardiac remodeling and outcomes after transcatheter edge-to-edge repair (TEER) are limited.
METHODS METHODS
A total of 78 patients with severe mitral regurgitation (MR) were included retrospectively. All patients had echocardiography at baseline and again six months after TEER. They were monitored for a primary composite endpoint, consisting of heart failure hospitalization and cardiovascular death, over 13 months.
RESULTS RESULTS
Significant decreases in the left ventricular ejection fraction (LVEF), all myocardial work indices (except global wasted work), and the left atrial reservoir were observed after TEER. Additionally, there was a decrease in the pulmonary artery systolic pressure and an increase in the tricuspid annular plane systolic excursion/pulmonary artery systolic pressure (TAPSE/PASP) ratio. A post-TEER TAPSE/PASP ratio of <0.47 (HR: 4.76,
CONCLUSIONS CONCLUSIONS
Echocardiography post-TEER reflects impairment in ventricular performance due to preload reduction and right ventricle and pulmonary artery coupling improvement. Short-term echocardiography after TEER identifies high-risk patients who could benefit from a close clinical follow-up. The prognostic significance of LA strain and the TAPSE/PASP ratio should be validated in subsequent large-scale prospective studies.

Identifiants

pubmed: 39200177
pii: biomedicines12081710
doi: 10.3390/biomedicines12081710
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Javier Solsona-Caravaca (J)

Cardiology Department, Hospital Vall d'Hebron, 08035 Barcelona, Spain.

Rubén Fernández-Galera (R)

Cardiology Department, Hospital Vall d'Hebron, 08035 Barcelona, Spain.

Víctor González-Fernández (V)

Cardiology Department, Hospital Vall d'Hebron, 08035 Barcelona, Spain.

Lorenzo Airale (L)

Internal Medicine Department, Città della Salute e della Scienza Hospital, 10126 Turin, Italy.

Johny Rivas (J)

Cardiology Department, Hospital Vall d'Hebron, 08035 Barcelona, Spain.

Luca Scudeler (L)

Cardiology Department, Città della Salute e della Scienza Hospital, 10126 Turin, Italy.

Núria Vallejo (N)

Cardiology Department, Hospital Vall d'Hebron, 08035 Barcelona, Spain.

Gisela Teixidó-Turà (G)

Cardiology Department, Hospital Vall d'Hebron, 08035 Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.

Guillem Casas (G)

Cardiology Department, Hospital Vall d'Hebron, 08035 Barcelona, Spain.

Filipa Valente (F)

Cardiology Department, Hospital Vall d'Hebron, 08035 Barcelona, Spain.

Ruper Oliveró (R)

Cardiology Department, Hospital Vall d'Hebron, 08035 Barcelona, Spain.

Yassin Belahnech (Y)

Cardiology Department, Hospital Vall d'Hebron, 08035 Barcelona, Spain.

Gerard Martí (G)

Cardiology Department, Hospital Vall d'Hebron, 08035 Barcelona, Spain.

Bruno García (B)

Cardiology Department, Hospital Vall d'Hebron, 08035 Barcelona, Spain.

Ignacio Ferreira-González (I)

Cardiology Department, Hospital Vall d'Hebron, 08035 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain.

José F Rodríguez-Palomares (JF)

Cardiology Department, Hospital Vall d'Hebron, 08035 Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.

Laura Galian-Gay (L)

Cardiology Department, Hospital Vall d'Hebron, 08035 Barcelona, Spain.
Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.

Classifications MeSH